Welcome to our dedicated page for Prenetics SEC filings (Ticker: PRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Prenetics Global Limited filings document a foreign private issuer that furnishes Form 6-K reports for material corporate updates, financial results and press-release exhibits. The filings cover the company’s IM8 consumer health and longevity business, including product and partnership announcements, operating results, registration-statement incorporation and disclosures tied to its focus on global expansion of the brand.
The filing record also documents capital allocation and governance matters, including Class A Ordinary Share repurchase authorization, executive open-market share purchases, board changes, treasury policy related to digital assets and completed divestiture activity such as the sale of the company’s Insighta equity interest. These disclosures frame Prenetics’ capital structure, liquidity commentary and reported business priorities as a public foreign issuer.
Cheng Yin Pan reported acquisition or exercise transactions in this Form 4 filing.
Prenetics Global Ltd director Cheng Yin Pan, through wholly owned entity M13 Capital Management Holdings Ltd, received a grant of 6,406 Restricted Stock Units under the company’s 2022 Share Incentive Plan. Each RSU represents the right to receive one Class A Ordinary Share.
The 6,406 RSUs are scheduled to vest on May 17, 2027, subject to continued service. After this grant, indirect holdings reported for this award total 22,279 RSUs. Vested RSUs are not automatically settled; delivery of Class A Ordinary Shares occurs at Cheng Yin Pan’s election in line with the company’s insider trading policy.
Prenetics Global Ltd director Cheng Yin Pan has amended insider disclosures to detail indirect holdings through M13 Capital Management Holdings Limited, a British Virgin Islands company wholly owned by him. M13 holds 43,178 Class A Ordinary Shares, 48,816 underlying warrant shares and 15,873 restricted stock units.
The warrants were originally issued in connection with Prenetics’ initial business combination completed on May 18, 2022 and, after a 1-for-15 reverse stock split on November 14, 2023, are exercisable for 48,816 Class A shares at an exercise price of $133.65 per 1.29 shares, or an effective $103.60 per share. The 15,873 RSUs vest on May 17, 2026 and each represents the right to receive one Class A share, with settlement timing elected by Cheng Yin Pan under the company’s insider trading policy.
Prenetics Global Ltd reported that Chief Financial Officer Lo Hoi Chun received a grant of 91,629 Restricted Stock Units (RSUs), each representing the right to receive one Class A ordinary share. These RSUs were granted under the company’s 2022 Share Incentive Plan as compensation.
The RSUs vest over time, with 7,635 RSUs vesting on May 19, 2026, 7,635.75 RSUs vesting on the 19th of each subsequent month through March 19, 2027 (total 76,358 shares), and 7,636 RSUs vesting on April 19, 2027. After this award, Lo Hoi Chun is reported as holding 597,930 RSUs.
Vested RSUs are not automatically converted into shares. Instead, settlement and delivery of Class A ordinary shares occur at Lo Hoi Chun’s election, in line with the company’s insider trading policy. This is a non-cash equity compensation grant, not an open-market share purchase or sale.
Prenetics Global Limited, parent of premium health brand IM8, announced a multi-year global partnership with author and podcast host Jay Shetty, who becomes IM8’s Global Ambassador and a shareholder in Prenetics. This expands IM8’s reach beyond sport into Shetty’s large wellness-focused audience.
The announcement comes as IM8 raises its full-year 2026 revenue guidance to $190 million to $210 million after reporting preliminary Q1 2026 IM8 revenue of $33.8 million, nearly six times higher year over year. IM8’s May 2026 monthly revenue is tracking at about $15.5 million, implying roughly $186 million in annualized recurring revenue.
Prenetics Global Limited, parent of premium health brand IM8, has appointed Brian J. Rosin as Chief Financial Officer of IM8. He brings nearly two decades of finance leadership in consumer e-commerce and wellness subscriptions and will report to CEO Danny Yeung.
The company highlights IM8 as one of the fastest-growing consumer health supplement brands, now sold in more than 40 countries and having surpassed $100 million in annualized recurring revenue within 11 months of launch. IM8 is projecting $190 million to $210 million in revenue for full year 2026, only its second year from launch, underscoring management’s expectations for rapid global expansion.
Prenetics Global Limited, parent of premium health brand IM8, has appointed Brian J. Rosin as Chief Financial Officer of IM8. He brings nearly two decades of finance leadership in consumer e-commerce and wellness subscriptions and will report to CEO Danny Yeung.
The company highlights IM8 as one of the fastest-growing consumer health supplement brands, now sold in more than 40 countries and having surpassed $100 million in annualized recurring revenue within 11 months of launch. IM8 is projecting $190 million to $210 million in revenue for full year 2026, only its second year from launch, underscoring management’s expectations for rapid global expansion.
Prenetics Global reported preliminary Q1 2026 revenue of $36.0 million, up sharply from $8.3 million a year earlier, driven by its IM8 premium nutrition brand. IM8 generated $33.8 million of revenue, compared with $5.7 million in Q1 2025, and improved gross margin to about 64%.
Company-wide gross profit was $23.3 million, with a loss from operations of $8.9 million and adjusted EBITDA loss of $5.6 million, showing the business is still investing for growth. Management now guides full-year 2026 IM8 revenue to $190–$210 million and expects Q2 2026 revenue of $46–$48 million, mostly from IM8.
Prenetics highlighted IM8’s subscription-led model, rising average order values, and expanding global footprint, with over 60% of IM8 revenue outside the U.S. The company remains debt-free and reported $56.0 million of cash at March 31, 2026, plus additional liquidity from divesting digital assets and investment funds, and has repurchased about $19 million of shares under a $40 million buyback program.
Prenetics Global reported preliminary Q1 2026 revenue of $36.0 million, up sharply from $8.3 million a year earlier, driven by its IM8 premium nutrition brand. IM8 generated $33.8 million of revenue, compared with $5.7 million in Q1 2025, and improved gross margin to about 64%.
Company-wide gross profit was $23.3 million, with a loss from operations of $8.9 million and adjusted EBITDA loss of $5.6 million, showing the business is still investing for growth. Management now guides full-year 2026 IM8 revenue to $190–$210 million and expects Q2 2026 revenue of $46–$48 million, mostly from IM8.
Prenetics highlighted IM8’s subscription-led model, rising average order values, and expanding global footprint, with over 60% of IM8 revenue outside the U.S. The company remains debt-free and reported $56.0 million of cash at March 31, 2026, plus additional liquidity from divesting digital assets and investment funds, and has repurchased about $19 million of shares under a $40 million buyback program.
Prenetics Global Limited announced that its IM8 brand has entered a multi-year partnership with Inter Miami CF, becoming the club’s exclusive Official Health Supplements Partner. The deal includes Inter Miami taking an equity stake in Prenetics, its first-ever equity position in a brand partner.
IM8 products such as Daily Ultimate Essentials, Daily Ultimate Longevity, and The Beckham Stack will be integrated into Inter Miami’s training facility for players and staff, supported by in-stadium branding and digital exposure. IM8 also receives group player name, image, and likeness rights for at least four players.
Since launching in December 2024, IM8 has surpassed $100 million in annualized recurring revenue, delivering more than 24 million servings across over 800,000 customer purchases in 40+ countries. The Company projects IM8 revenues of approximately $180 million to $200 million for full-year 2026.
Prenetics Global Limited plans to fully divest its treasury holdings of approximately 510 Bitcoin, targeting completion by May 14, 2026. Based on recent prices of about $80,000 per BTC, the company currently expects gross proceeds of roughly $40 million.
After the sale, Prenetics expects total cash, current financial assets and escrowed consideration to increase from about $112 million as of March 31, 2026 to approximately $145 million to $150 million, with no indebtedness. The Board has adopted a policy not to purchase Bitcoin or other digital assets going forward, focusing capital on the IM8 consumer health business, which is targeting $180 million to $200 million in FY2026 revenue.
The company intends to use divestment proceeds to potentially expand its up to $40 million share repurchase program, accelerate IM8 marketing, fund new product launches in Q4 2026 and support international expansion across more than 40 countries. Prenetics expects to report selected Q1 FY2026 results on May 14, 2026, when it also plans to disclose final Bitcoin sale proceeds and volume-weighted average price.
Prenetics Global Limited, a Cayman Islands holding company with operations primarily in Hong Kong, files its annual report describing its structure, risks and recent strategic shifts. As of December 31, 2025, it had 16,874,089 ordinary shares outstanding, including 15,293,117 Class A and 1,580,972 Class B shares, and 17,352,363 warrants.
The company reports net losses of $64.8 million, $49.8 million and $38.7 million for 2023, 2024 and 2025, reflecting heavy investment in marketing and growth. Selling and marketing expenses were $35.5 million in 2025, equal to 38.5% of revenue from continuing operations, as Prenetics builds its CircleDNA and IM8 consumer health brands.
Prenetics highlights legal and regulatory risks tied to operating in Hong Kong as a Special Administrative Region of China, including potential future application of PRC data and cybersecurity rules and evolving U.S.-China relations. It also discloses holding about 510 Bitcoin as a long-term treasury reserve, noting price volatility, regulatory uncertainty and custody risks that could materially affect its balance sheet and earnings under IFRS revaluation accounting.
Prenetics Global Ltd ownership update: Genetel Bioventures Ltd and Michael Yang Mengsu report beneficial ownership of 488,857 Class A Ordinary Shares, representing 3.3% of the Class A shares outstanding. The percentage is calculated on an aggregate of 14,697,463 Class A Ordinary Shares outstanding as of March 31, 2026.
The statement is filed by Genetel and Mr. Yang Mengsu and clarifies voting and dispositive powers shown on the cover page. Signatures on the amendment are dated April 22, 2025.